Abstract:Abstract Background and Aims Several patients with multiple myeloma suffered from more than one type of kidney disease simultaneously, of which the most common pattern is coexistent light chain cast nephropathy and light chain deposition disease (LCCN+LCDD). We investigated clinicopathological characteristics of LCCN+LCDD in comparison with pure LCCN and pure LCDD. Method Forty-seven percent of the renal biopsies revealed a monoclonal κ light chain restriction, ranging from 31% in the pure LCCN group to 90% in the pure LCDD group. Of note, more than half of the patients with LCCN+LCDD showed λ light chain isotype, which was significantly different from patients with pure LCDD (56% vs. 10%, p = 0.033). Compared with patients with pure LCDD, patients with LCCN+LCDD usually presented atypical features of LCDD with less nodular glomerulosclerosis (p = 0.003) and less diffuse deposit distribution (p = 0.027). Compared to patients with pure LCDD, patients with LCCN+LCDD had lower hemoglobin (126.5 g/L vs. 82.0 g/L, p = 0.008), higher incidence of AKI (20% vs. 89%, p = 0.003), lower percentage of urinary albumin excretion (%UAE) (68.9% vs. 5.1%, p = 0.003). There was no significant clinical difference between patients with LCCN+LCDD and patients with pure LCCN. Compared to patients with pure LCDD, patients with pure LCCN had lower hemoglobin (126.5 g/L vs. 87.0 g/L, p = 0.001), higher incidence of AKI (20% vs. 85%, p < 0.001), higher incidence of hemodialysis at diagnosis (10% vs. 65%, p = 0.003), higher serum creatinine (165.8 μmol/L vs. 627.0 μmol/L, p = 0.02) and lower incidence of hematuria (6/10 vs. 4/26, p = 0.035). Results Forty-seven percent of the renal biopsies revealed a monoclonal κ light chain restriction, ranging from 31% in the pure LCCN group to 90% in the pure LCDD group. Of note, more than half of the patients with LCCN+LCDD showed λ light chain isotype, which was significantly different from patients with pure LCDD (56% vs. 10%, p = 0.033). Compared with patients with pure LCDD, patients with LCCN+LCDD usually presented atypical features of LCDD with less nodular glomerulosclerosis (p = 0.003) and less diffuse deposit distribution (p = 0.027). Compared to patients with pure LCDD, patients with LCCN+LCDD had lower hemoglobin (126.5 g/L vs. 82.0 g/L, p = 0.008), higher incidence of AKI (20% vs. 89%, p = 0.003), lower percentage of urinary albumin excretion (%UAE) (68.9% vs. 5.1%, p = 0.003). There was no significant clinical difference between patients with LCCN+LCDD and patients with pure LCCN. Compared to patients with pure LCDD, patients with pure LCCN had lower hemoglobin (126.5 g/L vs. 87.0 g/L, p = 0.001), higher incidence of AKI (20% vs. 85%, p < 0.001), higher incidence of hemodialysis at diagnosis (10% vs. 65%, p = 0.003), higher serum creatinine (165.8 μmol/L vs. 627.0 μmol/L, p = 0.02) and lower incidence of hematuria (6/10 vs. 4/26, p = 0.035). Conclusion Pathologically, patients with LCCN+LCDD were more likely to have λ light chain isotype and presented atypical features of LCDD including less nodular glomerulosclerosis and less deposit distribution than patients with pure LCDD. In clinical characteristics, patients with LCCN+LCDD and patients with pure LCCN shared similar features. For patients with LCCD, especially those with λ restriction, nephrologists should carefully evaluate the kidney specimens to exclude the possibility of combined LCCN.

[Pulmonary light chain deposition disease from a respiratory physician's perspective]

[Retrospective clinicopathological analysis of pulmonary light chain deposition disease secondary to Sjögren's syndrome]

Nodular pulmonary light chain deposition disease: an entity associated with Sjögren syndrome or marginal zone lymphoma

Phenotypes and outcome of diffuse pulmonary non-amyloid light chain deposition disease

Light chain deposition disease presenting with gastrointestinal disorder as primary manifestation: report of two cases and literature review

Clinicopathological Characteristics of Light and Heavy Chain Deposition Disease: A Case Series

Advance in diagnosis and treatment of pulmonary lymphangitic carcinomatosis

Clinical and Pathological Analysis in Patients with Light-Chain Deposition Disease

Plasma cell myeloma initially diagnosed as light-chain deposition disease on liver biopsy: A case report and literature review

Light Chain Only Variant of Proliferative Glomerulonephritis with Monoclonal Immunoglobulin Deposits: a Clinicopathological Study of Three Cases

Light chain deposition disease: pathogenesis, clinical characteristics and treatment strategies

Diffuse Pulmonary Lymphangiomatosis: a Case Report with Literature Review.

An Adult Case of Diffuse Pulmonary Lymphangiomatosis

Clinicopathological Characteristics and Outcomes of Light Chain Deposition Disease: an Analysis of 48 Patients in a Single Chinese Center

MO158CLINICOPATHOLOGICAL FEATURES OF COEXISTENT LIGHT CHAIN CASE NEPHROPATHY AND LIGHT CHAIN DEPOSITION DISEASE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

PLCG2-associated immune dysregulation (PLAID) comprises broad and distinct clinical presentations related to functional classes of genetic variants

Castleman disease-associated diffuse parenchymal lung disease: A STROBE-compliant retrospective observational analysis of 22 cases in a tertiary Chinese hospital.

Emergent high fatality lung disease in systemic juvenile arthritis

Lung carcinoma with diffuse cysts repeatedly misdiagnosed as pulmonary infections and lymphoid interstitial pneumonia: A case report

Characterization of a Novel Pathogenic PLCG2 Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor.

A case of heavy-chain deposition disease with good long-term renal survival and a literature review